Full Text View
Tabular View
No Study Results Posted
Related Studies
Generation of Anti-HCV Antibodies From Bone Marrow: Defining the Repertoire of Immune Response to HCV Quasispecies
This study has been completed.
First Received: March 2, 2000   Last Updated: March 3, 2008   History of Changes
Sponsored by: National Institutes of Health Clinical Center (CC)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00004851
  Purpose

To generate a library of genes that reflect the entirety of antibody responses to hepatitis C virus (HCV) made during the 20-year course of HCV infection in a single patient (WH) whose viral quasispecies has been extensively characterized. In addition to characterizing the sequential events in antibody formation and their relationship to the changing pattern of viral quasispecies, we hope to identify neutralizing antibodies and the epitopes to which they are directed. Ultimately we seek to gain insight into the host mechanisms that suppress viral replication and to translate this to therapeutic and preventive modalities.


Condition
Hepatitis C

MedlinePlus related topics: Hepatitis Hepatitis C
Drug Information available for: Immunoglobulins Globulin, Immune
U.S. FDA Resources
Study Type: Observational
Official Title: Generation of Anti-HCV Antibodies From Bone Marrow: Defining the Repertoire of Immune Response to HCV Quasispecies

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 1
Study Start Date: April 1999
Estimated Study Completion Date: May 2001
Detailed Description:

To generate a library of genes that reflect the entirety of antibody responses to hepatitis C virus (HCV) made during the 20-year course of HCV infection in a single patient (WH) whose viral quasispecies has been extensively characterized. In addition to characterizing the sequential events in antibody formation and their relationship to the changing pattern of viral quasispecies, we hope to identify neutralizing antibodies and the epitopes to which they are directed. Ultimately we seek to gain insight into the host mechanisms that suppress viral replication and to translate this to therapeutic and preventive modalities.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Persistent infection with mild hepatitis that is non-progressive.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004851

Locations
United States, Maryland
Warren G. Magnuson Clinical Center (CC)
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

Publications:
Study ID Numbers: 990090, 99-CC-0090
Study First Received: March 2, 2000
Last Updated: March 3, 2008
ClinicalTrials.gov Identifier: NCT00004851     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
HCV Antibody Library

Study placed in the following topic categories:
Virus Diseases
Hepatitis
Antibodies
Liver Diseases
Digestive System Diseases
Immunologic Factors
Hepatitis, Viral, Human
Hepatitis C Antibodies
Hepatitis C
Immunoglobulins

Additional relevant MeSH terms:
Liver Diseases
RNA Virus Infections
Flaviviridae Infections
Immunologic Factors
Physiological Effects of Drugs
Hepatitis, Viral, Human
Pharmacologic Actions
Hepatitis
Virus Diseases
Antibodies
Digestive System Diseases
Hepatitis C
Hepatitis C Antibodies

ClinicalTrials.gov processed this record on May 07, 2009